Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 1/20 | 0.49 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.48 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.48 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.48 |
| ▸ | CCR2 | P41597 | 1/20 | 0.45 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.42 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.41 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1250934 | 0.88 | GP6 (0.51) | PLA2G4AAGTR1AGTR2GRM2CCR2 | |
| SCHEMBL1250386 | 0.88 | GRM2 (0.48) | PLA2G4AAGTR1AGTR2GRM2CCR2 | |
| SCHEMBL12892290 | 0.85 | GP6 (0.54) | PLA2G4AGRM2PFKFB3PDE7APDE7B | |
| SCHEMBL4096357 | 0.85 | RPA1 (0.52) | PLA2G4AAGTR1AGTR2GRM2CCR2 | |
| SCHEMBL4088569 | 0.84 | PLA2G4A (0.56) | PLA2G4AAGTR1AGTR2GRM2PTGDR2 | |
| SCHEMBL4103980 | 0.84 | GRM2 (0.48) | PLA2G4AAGTR1AGTR2GRM2CCR2 | |
| SCHEMBL4089239 | 0.84 | PLA2G4A (0.51) | PLA2G4AAGTR1AGTR2GRM2 | |
| SCHEMBL4088566 | 0.84 | GRM2 (0.49) | PLA2G4AAGTR1AGTR2GRM2PTGDR2 | |
| SCHEMBL1248028 | 0.84 | ATM (0.51) | PLA2G4AAGTR1AGTR2GRM2CCR2 | |
| SCHEMBL12914817 | 0.84 | PLA2G4A (0.48) | PLA2G4AAGTR1AGTR2GRM2CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879893-B2 | Zinc binding ligand; sustained release of insulin | NOVO NORDISK A/S (DK) | 2011-02-01 | — | — | US | disclosed |
| US-7879893-B2 | Zinc binding ligand; sustained release of insulin | NOVO NORDISK A/S (DK) | 2011-02-01 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| EP-1585541-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK AS (DK) | 2007-11-14 | — | — | EP | disclosed |
| EP-1585541-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK AS (DK) | 2007-11-14 | — | — | EP | disclosed |
| US-20060258561-A1 | Novel NPH insulin preparations | NOVO NORDISK A/S (DK) | 2006-11-16 | — | — | US | disclosed |
| CN-1787833-A | Pharmaceutical preparation comprising acid-stabilized insulin | NOVO NORDISK AS (DK) | 2006-06-14 | — | — | CN | disclosed |
| US-20060069013-A1 | Pharmaceutical preparations comprising acid-stabilised insulin | NOVO NORDISK A/S (DK) | 2006-03-30 | — | — | US | disclosed |
| US-20050065066-A1 | comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer; physical and chemical stability | NOVO NORDISK A/S (DK) | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258561-A1 | Novel NPH insulin preparations | IAPP, HBB, INSR | PLA2G4A 4850/4885AGTR1 972/4885AGTR2 1616/4885 |
| US-20060069013-A1 | Pharmaceutical preparations comprising acid-stabilised insulin | IAPP, GPR119, INSR | PLA2G4A 4116/4885AGTR1 1475/4885AGTR2 2403/4885 |
| US-20050065066-A1 | comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer; physical and chemical stability | IAPP, IRS1, INSR | PLA2G4A 4510/4885AGTR1 1033/4885AGTR2 2109/4885 |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | IAPP, IRS1, HBB | PLA2G4A 4747/4885AGTR1 2210/4885AGTR2 3244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.